Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged 18 to 55 years of age.~2. Fitzpatrick skin types I to III.~3. Must be able to comprehend and follow the requirements of the study~4. Avoid excessive sun exposure~5. Willing to refrain from topical product use on the back for the duration of the study.~6. Subjects must agree not to immerse their bandages in water for the duration of the study.~7. Male and female subjects with reproductive potential who agree to practice a medically acceptable form of birth control~Exclusion Criteria:~1. Excessively hairy back, acne, scars and pigmentation or nevi t~2. . Pregnant or Lactating, or planning on becoming pregnant;~3. . Known allergies or sensitivities to anesthetics, adhesive bandages, wound treatment products or tapes;~4. . Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results~5. Participation in any other clinical study within 30 days of Visit 1;~6. . Subjects who have a health condition and/or pre-existing or dormant dermatologic conditions or who have clinically active bacterial, fungal, or viral skin infections or those who are susceptible to cutaneous infections~7. Subjects who report using prescription or OTC medication (oral or topical) that can make skin more sensitive or influence the skin (i.e. antibiotics, hormones, insulin, etc.)~8. Subjects receiving topical and/or inhaled medications that may alter or compromise the bleeding/healing process~9. Individuals with a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications and/or radiation~10. . Subjects with a known history of keloid or hypertrophic scar formation;~11. Subjects diagnosed with any blood clotting disorder;~12. Hyperthyroidism or hypothyroidism or with active or recently treated (within 1 year) skin cancer, or those in poor nutritional status; 13 Subjects taking oral Vitamin A derivatives such as Accutane, isotretinon, or using retinoic acid in the past 1 year or using topical Vitamin A derivatives in the 3 weeks prior to study start;~14. Subjects with clinically infected skin lesions; 15. Subjects with cracked or excoriated skin, or other skin problems. 16. Diabetes mellitus that cannot be controlled by diet alone (i.e. requires systemic medications for control); 17. Subjects with friable skin, at the discretion of the Investigator;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ADHESIVE BANDAGE #1 (Type: EXPERIMENTAL): bandage applied to wounded site.
- ADHESIVE BANDAGE #2 (Type: EXPERIMENTAL): bandage applied to wounded site.
- ADHESIVE BANDAGE #3 (Type: EXPERIMENTAL): bandage applied to wounded site
- Antibacterial Bandage with 0.8% BZK (Type: EXPERIMENTAL): bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
- Intact and No Bandage (Type: OTHER): This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
- Wounded and No Bandage (Type: OTHER): This test site will be wounded and no bandage applied, serving as a positive control site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete